JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases
Authors:
- Bo-Shi ZhangBZBo-Shi Zhang
- Xiao-Meng ZhangXZXiao-Meng Zhang
- Masaaki ItoMIMasaaki Ito
- Satoshi YajimaSYSatoshi Yajima
- Kimihiko YoshidaKYKimihiko Yoshida
- Mikiko OhnoMOMikiko Ohno
- Eiichiro NishiENEiichiro Nishi
- Hao WangHWHao Wang
- Shu-Yang LiSLShu-Yang Li
- Masaaki KubotaMKMasaaki Kubota
- Yoichi YoshidaYYYoichi Yoshida
- Tomoo MatsutaniTMTomoo Matsutani
Open Access
- 30 April 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 4935
Abstract
Inflammation is closely associated with cerebrovascular diseases, cardiovascular diseases, diabetes, and cancers, and it is accompanied by the development of autoantibodies in the early stage of inflammation-related diseases. Hence, it is meaningful to discover novel antibody biomarkers targeting inflammation-related diseases. In this study, Jumonji C-domain-containing 6 (JMJD6) was identified by the serological identification of antigens through recombinant cDNA expression cloning. In particular, JMJD6 is an antigen recognized in serum IgG from patients with unstable angina pectoris (a cardiovascular disease). Then, the serum antibody levels were examined using an amplified luminescent proximity homogeneous assay-linked immunosorbent assay and a purified recombinant JMJD6 protein as an antigen. We observed elevated levels of serum anti-JMJD6 antibodies (s-JMJD6-Abs) in patients with inflammation-related diseases such as ischemic stroke, acute myocardial infarction (AMI), diabetes mellitus (DM), and cancers (including esophageal cancer, EC; gastric cancer; lung cancer; and mammary cancer), compared with the levels in healthy donors. The s-JMJD6-Ab levels were closely associated with some inflammation indicators, such as C-reactive protein and intima–media thickness (an atherosclerosis index). A better postoperative survival status of patients with EC was observed in the JMJD6-Ab-positive group than in the negative group. An immunohistochemical analysis showed that JMJD6 was highly expressed in the inflamed mucosa of esophageal tissues, esophageal carcinoma tissues, and atherosclerotic plaques. Hence, JMJD6 autoantibodies may reflect inflammation, thereby serving as a potential biomarker for diagnosing specific inflammation-related diseases, including stroke, AMI, DM, and cancers, and for prediction of the prognosis in patients with EC.Keywords
All Related Versions
Funding Information
- Japan Science and Technology Agency (14657335, JPMJSP2109, 17K16626, 19K09451, 20H03449, 20K07810, 20K08445, 20K17953, 21K19437, 22K07273, 22K09227, 22K19428)
- Japan Society for the Promotion of Science (14657335, JPMJSP2109, 17K16626, 19K09451, 20H03449, 20K07810, 20K08445, 20K17953, 21K19437, 22K07273, 22K09227, 22K19428)
This publication has 59 references indexed in Scilit:
- Targeting the JMJD6/TGF-β axis in prostate cancer by immunotherapy: A potential treatment based on RNA splicingMedical Hypotheses, 2023
- Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesisCancer and Metastasis Reviews, 2022
- Association of Ischemic Stroke Incidence, Severity, and Recurrence With Dementia in the Atherosclerosis Risk in Communities Cohort StudyJAMA Neurology, 2022
- Tumour- associated autoantibodies as prognostic cancer biomarkers- a reviewAutoimmunity Reviews, 2022
- Targeting the pathways of regulated necrosis: a potential strategy for alleviation of cardio-cerebrovascular injuryCellular and Molecular Life Sciences, 2020
- High serum PD‐L1 level is a poor prognostic biomarker in surgically treated esophageal cancerCancer Medicine, 2019
- Inflammation in human carotid atheroma plaquesCytokine & Growth Factor Reviews, 2018
- Tissue microarray profiling in human heart failureProteomics, 2016
- Endogenous Jmjd6 gene product is expressed at the cell surface and regulates phagocytosis in immature monocyte‐like activated THP‐1 cellsJournal of Cellular Physiology, 2009
- Autoantibody markers for the diagnosis and prediction of type 1 diabetesAutoimmunity Reviews, 2006